Drugs / HT-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06746311 | Nov 2022 → May 2024 | chronic hepatitis B virus infection | Suzhou HepaThera Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07183306 | Dec 2024 → Aug 2026 overdue | chronic hepatitis B virus infection | Suzhou HepaThera Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07245953 | Nov 2025 → Feb 2027 expected | chronic hepatitis B virus infection | Suzhou HepaThera Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-21 | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Results Towards the Functional Cure of HBV: Biomissile Announces Breakthrough Clinical Results for BM012 (HT-102) at AASLD 2025 biomissile.com ↗
November 2025 – Biomissile Pharmaceuticals Co., Ltd. and Suzhou HepaThera Biotech Co. Ltd. announced positive results from a randomized, multicenter phase Ib/IIa study of BM012 (HT-102) in combination with HT-101 in patients with chronic hepatitis B (HBV). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-21 | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Towards the Functional Cure of HBV: Biomissile Announces Breakthrough Clinical Results for BM012 (HT-102) at AASLD 2025 biomissile.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07245953 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06746311 ↗ |